Virobay Inc. and LEO Pharma Initiate a Phase 1 Trial of VBY-891, a Compound Intended for Oral Treatment of Psoriasis
(Logo: http://photos.prnewswire.com/prnh/20130221/595427)
The first Phase 1 trial of VBY-891 is a double-blind, randomized, placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple escalating doses of VBY-891 in healthy adults.
"The initiation of this Phase 1 trial represents a significant development objective for Virobay's collaboration with LEO Pharma," stated Robert Booth, Ph.D., Chief Executive Officer of Virobay. "Virobay has plans to initiate clinical studies with additional cathepsin inhibitors during2013 as we seek to develop new therapies for underserved diseases. Published prelinical data suggest that cathepsin S inhibition may provide a therapeutic benefit in patients with dermatological disorders such as psoriasis. In addition, our own preclinical data with selective cathepsin S inhibitors has demonstrated efficacy in models of both psoriasis and atopic dermatitis," stated Robert Booth. "We look forward to assessing the data from these Phase 1 trials, which will incorporate the evaluation of several biomarkers, to guide our Phase 2 clinical development plans for VBY-891."
"Reaching this important milestone in our collaboration with Virobay brings us one step closer to provide an oral treatment for psoriasis patients. We believe thatVBY-891 has the potential to provide an oral treatment that may alleviate symptoms of psoriasis. LEO Pharma strives to constantly expand and improve treatment options for patients and this is an important example of our commitment to meeting patient needs. To the best of our knowledge, theVBY-891 compound has the potential to be the first in class on the market," said Kim Kjøller, Senior Vice President, Global Development, LEO Pharma.
Background
About Cathepsin S and VBY-891
Cathepsin S is a member of the cysteine protease family of cathepsin inhibitors that catalyzes the final proteolytic step in the processing of invariant chain in specific antigen presenting cells. This step is essential in the maturation and loading of MHC Class II with antigenic peptides and subsequent activation of CD4+ T cells. Continuous presentation of antigenic self-peptides is thought to be involved in the maintenance of chronic disease in autoimmune disorders, including psoriasis. Inhibition of cathepsin S is likely to result in a reduction in antigen presentation without an impact on innate immunity.
VBY-891 is a next generation cathepsin S inhibitor that is a potent, competitive and reversible inhibitor of purified cathepsin S. It has picomolar inhibitory potency against the cathepsin S enzyme and nanomolar inhibitory potency in cellular assays.VBY-891 is also highly selective against human cathepsins L, B, F and K. Sustained cathepsin S inhibition after oral dosing has been demonstrated in vivo through the use of a biomarker. VBY-891 shows potent inhibitory activity in models of autoimmunity and neuropathic pain. Therefore, inhibition of cathepsin S may have therapeutic potential across a range of dermatological conditions.
About the collaboration
The multi-million dollar collaboration between Virobay Inc. and LEO Pharma A/S was entered in 2012when LEO Pharma in-licensed the promising compound from Virobay. The collaboration agreement involves up-front payment to Virobay of USD 7m, followed by milestone payments totalling up to USD 300m and tiered to royalties. The compound has been tested in pre-clinical studies and the project is now entering the next phase - a phase 1clinicaltrial in healthy human volunteers. After this trial has been completed, the plan is to do testing on psoriasis patients later this year. If the process proceeds as planned, the collaboration may result in an oral treatment for psoriasis in 6-7 years.
About Virobay, Inc.
Founded in 2006, Virobay is a leader in the design, synthesis and development of small molecule inhibitors of cysteine proteases, a class of enzymes that are key mediators in a variety of diseases, including autoimmunity, neuropathic pain, liver disease, cancer and cardiovascular disorders. Virobay's clinical pipeline currently includes product candidates in autoimmune disease, neuropathic pain and liver fibrosis. For more information, please visit www.virobayinc.com
About LEO Pharma
LEO Pharma helps people achieve healthy skin. By offering care solutions to patients in more than 100 countries globally, LEO Pharma supports people in managing their skin conditions. Founded in 1908 and owned by the LEO Foundation, the healthcare company has devoted decades of research and development to delivering products and solutions to people with skin conditions. LEO Pharma is headquartered in Denmark and employs approximately 5,000 people worldwide.
For more information, visit www.leo-pharma.com.
SOURCE Virobay, Inc. and LEO Pharma A/S
FONTE Virobay, Inc. and LEO Pharma A/S